Out-Law News | 06 Feb 2020 | 3:05 pm | 3 min. read
To get a single authorisation for selling new medicines across the whole of the EU, medicines manufacturers must apply to the EMA for marketing authorisation.
Catherine Drew of Pinsent Masons, the law firm behind Out-Law, said, though, that it is not clear what further steps manufacturers that submit their applications to the EMA during the Brexit transition period will be required to undertake in order to be authorised to sell those medicines in both EU27 countries and the UK once the transition period ends on 31 December this year.
What clients want to know and where guidance from the UK and EMA is currently lacking, is what happens after 31 December 2020 and what steps must be taken and timelines for the same, to ensure that applications currently pending before the EMA result in granted marketing authorisations valid in both Europe and the UK
The issue remains uncertain despite the publication of new Brexit 'Q&A' guidance earlier this week by the EMA, she said.
"What clients want to know and where guidance from the UK and EMA is currently lacking, is what happens after 31 December 2020 and what steps must be taken and timelines for the same, to ensure that applications currently pending before the EMA result in granted marketing authorisations valid in both Europe and the UK," Drew said.
In a recent statement, the EMA set out what the Brexit transition period means for pharmaceutical companies carrying out activities in the UK, and what actions they should take to be able to continue their operations as normal in 2021.
"During the transition period, EU pharmaceutical law … will continue to be applicable to the UK, meaning that pharmaceutical companies can continue to carry out activities in the UK until the end of the year," the EMA's statement said. "Companies have until 31 December 2020 to make the necessary changes to ensure that their authorised medicines comply with EU law and can remain on the EU market. Marketing authorisation holders / applicants can still be established in the UK and Qualified Persons for Pharmacovigilance (QPPVs) and pharmacovigilance system master files (PSMFs), as well as quality control testing sites, can still be based in the UK until the end of 2020."
In its new Brexit guidance, the EMA stated that there will be no "Brexit-related shortages of human or veterinary medicines" during the transition period. It outlined the actions being taken in the EU to avoid shortages arising after Brexit, which include encouraging UK-based pharmaceutical companies to transfer "essential operations" to within the EU or wider European Economic Area.
The EMA said: "If a company does not transfer relevant operations from the UK to one of the remaining EU/EEA member states in time before the 31 December 2020, the company may no longer be able to put the medicine on the market until it has made the necessary changes. These changes have to occur within a certain timeframe."
"EU/EEA authorities cannot force companies to act but it is in the companies’ interest to do so if they want to continue to serve the needs of patients and animals in the EU. EMA, the [European Commission] and EU/EEA member states have been monitoring the situation and advising companies on the necessary steps to take and urging them to make these changes in time in order to allow continued availability of medicines after the transition period. However, ultimately the responsibility to transfer relevant activities and to continue marketing a medicine in the EU/EEA lies with the company holding the medicine’s marketing authorisation," it said.
The EMA also urged pharmaceutical companies to take action in areas beyond the control of the EU authorities to "minimise the potential for supply disruptions after the transition period".
Catherine Drew of Pinsent Masons explained that the UK's exit from the EU on 31 January also has an immediate impact on the role the UK's The Medicines and Healthcare products Regulatory Agency (MHRA) can play in the decentralised procedure for medicine authorisations.
The decentralised procedure is another route by which companies can obtain marketing authorisation for medicinal products, currently for use in the UK and EU member states. While the EMA procedure provides manufacturers with scope to obtain a single authorisation for marketing medicines across all of the EU and EEA, the decentralised procedure offers medicines manufacturers scope to obtain a bundle of national authorisations for marketing medicines via a system of mutual recognition that national medicines regulators in the EU and EEA participate in.
"Previously UK-based manufacturers seeking a bundle of national authorisations in certain EU states including the UK would be able to apply to the MHRA under the decentralised procedure," Drew said. "Within their application they could designate other EU member states in which they wished to obtain authorisation to sell their products. The MHRA would then lead the assessment of that application which would be discussed between the agencies of all those EU member states designated in the application."
"Now, however, as the UK has formally exited the EU, the MHRA can no longer lead these types of assessments. If a UK-based company wants an EU marketing authorisation they need to apply to the EMA, or apply under the decentralised procedure but using a different national agency based in an EU country as the reference agency. The UK can be listed as a concerned member state within that application during the Brexit transition period," she said.
28 Jan 2020
26 Feb 2019